Characteristics of systemic testosterone therapy for female hypoactive sexual desire disorder-a claims database analysis

• Published in: Journal of sexual medicine 2024-03, Vol.21 (4), p.288-293
• Main Authors: Agrawal, Pranjal, Lee, Yeonsoo Sara, Grutman, Aurora J, Dumas, Kathryn, Kohn, Taylor, Kohn, Jaden, Yee, Alyssa M, Clifton, Marisa
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Estrogens - therapeutic use; Female; Humans; Libido; Middle Aged; Premenopause; Sexual Dysfunction, Physiological - chemically induced; Sexual Dysfunctions, Psychological - diagnosis; Sexual Dysfunctions, Psychological - drug therapy; Sexual Dysfunctions, Psychological - epidemiology; Testosterone; Young Adult
• ISSN: 1743-6095; 1743-6109; 1743-6109
• DOI: 10.1093/jsxmed/qdae013

Testosterone therapy (TTh) is recommended for postmenopausal women with hypoactive sexual desire disorder (HSDD); however, there remain insufficient data to support use of TTh in premenopausal women with sexual dysfunction. In this study, we used a large national database to evaluate prescribing trends of TTh for women with HSDD. We conducted a cohort analysis of information from electronic health records acquired from the data network TriNetX Diamond. The study cohort consisted of women 18-70 years of age with a diagnosis of HSDD. We analyzed trends of testosterone prescriptions, routes of testosterone administration, and coadministration of testosterone with estrogen. Despite an increase in rates of testosterone prescriptions for HSDD, there remains a high degree of variability in the duration of treatment, route of administration, and coadministration of estrogen with significant underprescription of testosterone. Our query of the TriNetX database led to the identification of 33 418 women diagnosed with HSDD at a mean age of 44.2 ± 10.8 years, among whom 850 (2.54%) women received a testosterone prescription. The testosterone prescriptions were highly variable with regard to duration and route of administration and coadministration with estrogen. For all patients until 2015, the prevalence of testosterone prescriptions for HSDD showed a positive quadratic relation was observed. Since 2015 a linear increase in prevalence was observed, with the highest rate of increase for patients aged 41-55 years. The findings of this study reveal a significant need for further research investigating the optimal use of TTh to enhance the sexual health of women with HSDD, and further studies on the long-term effects of testosterone use must be undertaken to ensure that patients have access to safe and effective treatment. Limitations to this study include patient de-identification and lack of availability of testosterone dosage data. However, this study also has many strengths, including being the first, to our knowledge, to characterize the prescribing trends of testosterone for women with HSDD. Testosterone therapy should be considered as a potential therapy for premenopausal female patients with HSDD. Further studies on the long-term effects of testosterone use must be undertaken to address disparities in the management of HSDD and to ensure patients can access treatment.